Regeneron Pharmaceuticals Future Growth

Future criteria checks 1/6

Regeneron Pharmaceuticals is forecast to grow earnings and revenue by 10.6% and 7.7% per annum respectively. EPS is expected to grow by 10.4% per annum. Return on equity is forecast to be 15.7% in 3 years.

Key information

10.6%

Earnings growth rate

10.4%

EPS growth rate

Biotechs earnings growth	29.6%
Revenue growth rate	7.7%
Future return on equity	15.7%
Analyst coverage	Good
Last updated	09 Sep 2024

Recent future growth updates

No updates

Recent updates

Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?

Sep 09

Regeneron Stock: Valuation Now Demands More Growth

Aug 26

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 81% Above Its Share Price

Aug 22

Risks To Shareholder Returns Are Elevated At These Prices For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Aug 04

Regeneron's Robust Pipeline And Financial Health Signal Continued Growth

Aug 02

Regeneron: Downgrading My Outlook To 'Hold' Ahead Of Q2 Earnings

Jul 11

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) CEO Compensation Looks Acceptable To Us And Here's Why

Jun 08

These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

May 21

Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks

May 06

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Popularity With Investors Is Under Threat From Overpricing

Apr 30

Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 47% Undervaluation?

Apr 10

Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate

Mar 26

Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings

Feb 16

Regeneron Pharmaceuticals: Time To Change My Strategy After Encouraging Q4 2024

Feb 10

Regeneron's Push Into Obesity, Q4 2023 Earnings Review

Feb 02

These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

Jan 31

Earnings and Revenue Growth Forecasts

NasdaqGS:REGN - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	16,448	5,193	5,864	5,557	21
12/31/2025	15,369	4,433	5,303	5,275	25
12/31/2024	14,148	4,230	5,264	5,544	24
6/30/2024	13,489	4,322	3,184	4,071	N/A
3/31/2024	13,100	3,858	3,930	4,739	N/A
12/31/2023	13,117	3,954	3,668	4,594	N/A
9/30/2023	13,097	3,991	4,359	5,224	N/A
6/30/2023	12,671	4,299	3,004	4,739	N/A
3/31/2023	12,370	4,183	2,527	4,281	N/A
12/31/2022	12,173	4,338	3,398	5,015	N/A
9/30/2022	13,710	5,370	4,148	5,668	N/A
6/30/2022	14,227	5,687	7,869	8,452	N/A
3/31/2022	16,508	7,934	7,936	8,515	N/A
12/31/2021	16,072	8,075	6,529	7,081	N/A
9/30/2021	13,543	6,996	5,381	5,940	N/A
6/30/2021	12,384	6,205	1,694	2,272	N/A
3/31/2021	9,198	4,004	2,029	2,589	N/A
12/31/2020	8,497	3,513	2,004	2,618	N/A
9/30/2020	7,938	3,156	1,582	2,175	N/A
6/30/2020	7,387	2,984	2,425	2,986	N/A
3/31/2020	7,013	2,279	1,706	2,231	N/A
12/31/2019	6,558	2,116	2,000	2,430	N/A
9/30/2019	6,622	2,144	1,995	2,371	N/A
6/30/2019	6,542	2,069	1,906	2,267	N/A
3/31/2019	6,572	2,428	2,095	2,473	N/A
12/31/2018	5,146	2,444	1,812	2,195	N/A
9/30/2018	6,365	1,798	1,628	2,033	N/A
6/30/2018	6,203	1,591	1,636	1,995	N/A
3/31/2018	6,065	1,428	N/A	1,570	N/A
12/31/2017	5,872	1,199	N/A	1,307	N/A
9/30/2017	5,517	1,278	N/A	1,118	N/A
6/30/2017	5,236	1,155	N/A	1,354	N/A
3/31/2017	4,979	963	N/A	1,784	N/A
12/31/2016	4,860	896	N/A	1,486	N/A
9/30/2016	4,732	797	N/A	1,377	N/A
6/30/2016	4,649	743	N/A	1,619	N/A
3/31/2016	4,435	741	N/A	1,477	N/A
12/31/2015	4,104	636	N/A	1,331	N/A
9/30/2015	3,808	571	N/A	1,247	N/A
6/30/2015	3,396	444	N/A	519	N/A
3/31/2015	3,063	346	N/A	597	N/A
12/31/2014	2,820	338	N/A	752	N/A
9/30/2014	2,628	345	N/A	831	N/A
6/30/2014	2,499	403	N/A	759	N/A
3/31/2014	2,291	394	N/A	551	N/A
12/31/2013	2,105	414	N/A	589	N/A
9/30/2013	1,909	798	N/A	400	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: REGN's forecast earnings growth (10.6% per year) is above the savings rate (2.5%).

Earnings vs Market: REGN's earnings (10.6% per year) are forecast to grow slower than the US market (15% per year).

High Growth Earnings: REGN's earnings are forecast to grow, but not significantly.

Revenue vs Market: REGN's revenue (7.7% per year) is forecast to grow slower than the US market (8.6% per year).

High Growth Revenue: REGN's revenue (7.7% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: REGN's Return on Equity is forecast to be low in 3 years time (15.7%).

Regeneron Pharmaceuticals Future Growth

Future criteria checks 1/6

Key information

Recent future growth updates

Recent updates

Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?

Senior VP of Finance & CFO recently sold US$6.4m worth of stock

Regeneron Pharmaceuticals, Inc Announces Ordspono (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

Regeneron Stock: Valuation Now Demands More Growth

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 81% Above Its Share Price

Regeneron Provides Update on Biologics License Application for Linvoseltamab

Executive Vice President of Research exercised options and sold US$15m worth of stock

Insider recently sold US$5.6m worth of stock

Risks To Shareholder Returns Are Elevated At These Prices For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Regeneron's Robust Pipeline And Financial Health Signal Continued Growth

Regeneron: Downgrading My Outlook To 'Hold' Ahead Of Q2 Earnings

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Approval in the European Union as the First-Ever Targeted Therapy for Patients with COPD

Regeneron Pharmaceuticals, Inc. Announces Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

Regeneron Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Regeneron Pharmaceuticals, Inc Announces Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine

Executive VP exercised options and sold US$5.6m worth of stock

Regeneron Pharmaceuticals, Inc. Announces 14-Month Median Follow-Up Data from the Pivotal Phase 1/2 Linker-MM1 Trial of Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma

Co-Founder exercised options and sold US$1.0m worth of stock

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) CEO Compensation Looks Acceptable To Us And Here's Why

Regeneron Pharmaceuticals, Inc and Sanofi Announces Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc. Announces Positive New Results from an Ongoing Phase 1/2 Trial Evaluating its First-in-Class Costimulatory Bispecific Antibody, REGN7075 (EGFRxCD28)

Regeneron Pharmaceuticals, Inc. and Sanofi Presents Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in the New England Journal of Medicine

These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

Co-Founder exercised options and sold US$104m worth of stock

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application (sBLA) for Dupixent

Regeneron Pharmaceuticals, Inc. Announces Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness Within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks

Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks

New minor risk - Shareholder dilution

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) announces an Equity Buyback for $3,000 million worth of its shares.

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Popularity With Investors Is Under Threat From Overpricing

Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 47% Undervaluation?

Regeneron Pharmaceuticals, Inc. Announces Positive Pivotal Data from the Phase 1/2 LINKER-MM1 Trial of Linvoseltamab in Patients with Heavily Pre-Treated Multiple Myeloma

Regeneron Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2024

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) completed the acquiistion of R&D pipeline from 2seventy bio, Inc. (NasdaqGS:TSVT) for $20 million.

Regeneron Pharmaceuticals, Inc Provides Update on Biologics License Application for Odronextamab

Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate

Executive Vice President of Research exercised options and sold US$11m worth of stock

Regeneron Pharmaceuticals, Inc.'s Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol

Regeneron Pharmaceuticals, Inc. Announces the Lancet Published One-Year Results from the Pivotal Pulsar and Photon Trials for EYLEA HD (Aflibercept) Injection 8 Mg

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts Dupixent®? (Dupilumab) Sbla for Treatment of Copd with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc. Announces Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review

Co-Founder exercised options and sold US$68m worth of stock

Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings

Regeneron Pharmaceuticals, Inc. and Sanofi Announces the Ministry of Health, Labor and Welfare in Japan Grants Marketing and Manufacturing Authorization for Dupixent (Dupilumab) for the Treatment of Chronic Spontaneous Urticaria

Insider exercised options and sold US$14m worth of stock

Regeneron Pharmaceuticals: Time To Change My Strategy After Encouraging Q4 2024

Insider recently sold US$7.6m worth of stock

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Regeneron Pharmaceuticals, Inc. Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma

Regeneron's Push Into Obesity, Q4 2023 Earnings Review

Regeneron Pharmaceuticals, Inc. Appoints Jason Pitofsky as Controller, Expects to Occur on February 5, 2024

These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

Regeneron Pharmaceuticals, Inc. and Sanofi Announce That U.S. Food and Drug Administration Approves Dupixent®? (Dupilumab) for the Treatment of Children Aged 1 Year and Older with Eosinophilic Esophagitis

Independent Director notifies of intention to sell stock

Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Updates the Label for Dupixent (Dpilumab)

Regeneron Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 02, 2024

Senior VP notifies of intention to sell stock

Regeneron Pharmaceuticals, Inc. Announces New and Updated Data for Odronextamab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Pivotal Trial Showed Deep and the Potential of ctDNA to Predict Long-Term Outcomes

Regeneron Pharmaceuticals, Inc. Announces Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma

Executive Vice President of Research exercised options and sold US$11m worth of stock

Regeneron Pharmaceuticals, Inc. Announces Presentation of New and Updated Data on Multiple Combination Therapies from its Oncology Pipeline at ESMO IO Congress 2023

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies